💡 The facility will house a range of production scales and benefit from AKB’s oligo manufacturing equipment.
🤝 The partnership aims to meet the growing needs of the oligonucleotide therapeutics field and foster innovation.
⏳ Operations at the facility are planned to start in late 2024.
Introduction:
Asahi Kasei Bioprocess (AKB) and Axolabs have formed a strategic partnership to accelerate the development and commercialization of oligonucleotide therapeutics. The companies are collaborating to build a manufacturing facility in Berlin that aims to meet the growing needs of the oligonucleotide therapeutics field.
- AKB and Axolabs are partnering to build a 59,000 ft2 manufacturing facility in Berlin for oligonucleotide therapeutics.
- The facility will accommodate a range of production scales and will benefit from AKB’s oligo manufacturing equipment.
- The partnership aims to foster innovation and drive the production of high-quality oligonucleotide therapeutics.
- Operations at the facility are planned to commence in late 2024.
Conclusion:
The partnership between AKB and Axolabs in the field of oligonucleotide therapeutics aims to accelerate the development and commercialization of these therapies. The construction of a manufacturing facility in Berlin will provide the necessary infrastructure to meet the growing demand for oligo-based therapies. This collaboration has the potential to foster innovation and contribute to the production of high-quality oligonucleotide therapeutics.
